



SAVE THE DATE

**ASCO Direct™
GU Highlights
Meeting 2024**

February 2nd, 2024 | Zürich and virtual
Update in Genitourinary Cancers

Registration:

<https://medicinematters.com/asco-direct-gu-highlights-switzerland/>

PROGRAM

Friday, February 2nd, 2024 | 14:30–19:30

14:30–14:35	Introduction	Jörg Beyer, Aurelius Omlin
14:35–16:00	Prostate Session	Aurelius Omlin, Alexandros Papachristofilou, Thomas Hermanns, Jonathan Hollmann
	Thomas Hermanns	<i>Introduction</i>
	Scott E. Eggener	<i>Abstract 262: Stockholm3 validation in a multi-ethnic cohort for prostate cancer (SEPTA) detection: A multicentered, prospective trial.</i>
	Alexandros Papachristofilou	<i>Introduction</i>
	Christophe Hennequin	<i>Abstract LBA 259: Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial.</i>
	Aurelius Omlin	<i>Introduction</i>
	Neeraj Agarwal	<i>Abstract 18: CONTACT-2: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).</i>
16:00–16:15	Break	
16:15–17:45	Renal Cell Carcinoma	Ursula Vogl, Katharina Hoppe, Sara Merler
	Ursula Vogl	<i>Introduction</i>
	Robert Motzer	<i>Abstract LBA 358: Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.</i>
	Toni Choueiri	<i>Abstract LBA359: Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).</i>
	Katharina Hoppe	<i>Introduction</i>
	Maria Teresa Bourlon	<i>Abstract: 362: Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.</i>
	Nizar M. Tannir	<i>Abstract 363: Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.</i>

17:45–18:00 Coffee Break

18:00–19:25 **Urothelial Carcinoma** Anja Lorch, Christian Fankhauser, Fabian Aschwanden

Christian Fankhauser	<i>Introduction</i>
Matthew Nicholas Young	<i>Abstract 534: Predictive value of dynamic changes in ctDNA and baseline biomarkers with neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial.</i>
Andrea B. Apolo	<i>Abstract LBA 531: AMBASSADOR Alliance A031501: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation.</i>
Anja Lorch	<i>Introduction</i>
Michiel Simon Van Der Heijden	<i>Abstract LBA 530: Enfortumab vedotin (EV) in combination with pembrolizumab (P) versus chemotherapy in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC): Subgroup analyses results from EV-302, a phase 3 global study.</i>
Rohit K. Jain	<i>Abstract 539: Cabozantinib plus pembrolizumab as first-line therapy for cisplatin-ineligible advanced urothelial carcinoma (PemCab)</i>

19:25–19:30 **Closing Remarks** Jörg Beyer, Aurelius Omlin

The **ASCO Direct™ GU Highlights Meeting 2024** is a full-day educational program containing selected original sessions from the **2024 ASCO Genitourinary Cancers Symposium** on urothelial carcinoma, prostate and renal cancers. Each session will be introduced by the scientific committee and guest speakers and you will have the opportunity to view the original presentations and discuss with your colleagues the clinical relevance and implications for Swiss treatment landscape.

The program is supervised by an independent scientific committee:

- **Prof. Dr. med. Jörg Beyer**, Inselspital Bern
- **PD Dr. med. Aurelius Omlin**, Onkzentrum Zürich

GU Cancer Experts:

- **Dr. med. Alexandros Papachristofilou**, Universitätsspital Basel
- **PD Dr. med. Thomas Hermanns**, Hirslanden Zürich
- **PD Dr. med. Ursula Vogl**, Ente Ospedaliero Cantonale
- **Dr. med. Katharina Hoppe**, Stadtspital Triemli
- **Prof. Dr. med. Anja Lorch**, Universitätsspital Zürich
- **PD Dr. med. Christian Fankhauser**, Luzerner Kantonsspital

Register now:



The cost of the event registration is CHF 150.–. It includes the participation to the seminar and individual access to all the videos and slides from the 2024 ASCO Genitourinary Cancers Symposium in the ASCO Website. The cost paid by the sponsors (CHF 300) will be disclosed.

By registering for this symposium you confirm that you agree to the recording of this virtual meeting. We use your provided data exclusively in connection with this event.

Please read our privacy policy at www.janssen.com/switzerland. The symposium is only CME accredited for the live participation.

We are very much looking forward to welcoming you to the symposium in February 2024.

Kind regards your faculty



ASCO Direct™



CH_EM-144130

Date: **February 2nd, 2024 | 14:30–19:30**

Location: **Hotel AMERON | Bellrive au Lac | Utoquai 47, 8008 Zürich**

ASCO Direct™ is an officially licensed program of the American Society of Clinical Oncology®. ASCO® is a registered trademark of the American Society of Clinical Oncology. All rights reserved. ASCO® does not endorse any health care product, therapy, diagnostic test or device.